Funded Tech Companies
Revance Therapeutics
Looking for the VC firms that invested in Revance Therapeutics? Private investors, Palo Alto Investors and NovaQuest put venture money into this innovative biopharmaceutical company.
Company Overview
Company Name
Revance Therapeutics
Company Status
Publicly-held
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
1222 Demonbreun St. 2000
Nashville, TN 37203
USA
Nashville, TN 37203
USA
Phone
Website
Email Address
Company Background Information
Overview
Revance (NASDAQ: RVNC) is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance's platform technologies to enhance patient tolerability of botulinum toxin.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
2/6/2014
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Foley
Chief Financial Officer
Tobin Schilke
Chief Operating Officer
Abhay Joshi
VP - Bus. Development
Dustin Sjuts
VP - Human Resources
Justin Ford
Company Investors
- Palo Alto Investors
- NovaQuest (Jonathan Tunnicliffe)
- Vivo Capital (Frank Kung)
- Technology Partners (James Glasheen)
- Pac-Link Bio
- Shepherd Ventures
- EW Healthcare Partners (Phyllis Gardner)
- EW Healthcare Partners (Ron Eastman)
- Leader Ventures (Brian Best)
- Horizon Technology Finance (Kevin May)
- Medicis Pharmaceutical (Jonah Shacknai)
Browse more funded tech companies:
Revamp Medical | Revascular Therapeutics
Share this article
About Our VC & M&A Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs